UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) (State or other jurisdiction of incorporation or organiza ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 14, 2024 12:40 PM ET Company Participants Jacque Shea - President and CEO Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great, thank you operator for again, always making this so seamless and easy for us all. We have now Jacque Shea, the President and CEO of Inovio Company we've been covering for a while now. And we recently upgraded on the back of some really compelling data ...

Precancerous Anal Dysplasia: Phase 2 open-label trial n=24 3 or 4 dose regimen at Months 0, 1, 3 and Week 36 (optional) Final findings (6 months after start of treatment) Clearance of HPV 16/18+ lesions: 50% of patients The Spontaneous Rate is estimated to be less than 27% • VGX-3100: composed of plasmids encoding for HPV-16 and HPV-18 subtypes; E6 and E7 oncogenes • Open-label trial of VGX-3100 in 24 HIV-negative participants with HPV-16 and/or -18-positive anal HSIL • 50% (11/22 evaluable) of participants ...

The research was recently featured on the Today Show, highlighting both the potential of DNA medicine and the power of partnerships to help accelerate progress for patients. We aim to continue building strategic partnerships like this one to drive medical progress for patients, innovation, and ultimately shareholder value. We also remain encouraged by the final data reported earlier this year from the study of INO-3112 in head and neck cancer in combination with a PD-L1 checkpoint inhibitor. We are continui ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Participants Jacqueline Shea - President and Chief Executive Officer Conference Call Participants Li Chen - H.C. Wainwright Li Chen Good afternoon, everyone, and welcome to H.C. Wainwright 25th Annual Global Investment Conference. My name is Li Chen, and I'm H.C. Wainwright Equity Research Associate. I'd like now to welcome our next speaker, Dr. Jacqueline Shea, Presi ...

As we've shared previously, in our recent Phase 1/2 trial, which included patients who had two or more surgeries in the prior year, 81% saw a reduction in surgical interventions as compared to the year prior to treatment. Patients and advocates have expressed time and again that a reduction in even one surgery would have a profound impact. Moving on to VGX-3100. As announced in our press release, Inovio will cease further development of VGX3100 as a potential treatment for cervical HSIL in the U.S. This dec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 660 W. Germantown Pike, Suite 110 Plymouth Meeting, Pennsylvania 19462 (Address of principal executive offices) (Zip Code) (I.R.S. Employ ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 4:05 PM ET Company Participants Greg Renza - Biotechnology Equity Research Analyst, RBC Conference Call Participants Jacqueline Shea - President & CEO Greg Renza Great. So welcome back to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, I'm one of the biotechnology equity research analyst here at RBC and we're pleased now to be joined by Inovio Pharmaceuticals and representing the co ...

Next, I'd like to share some highlights on the cellular and immune response we saw in this trial. Treatment induced cellular responses against both HPV-6 and HPV-11, inducing both activated CD4 and activated lytic CD8 T-cells. We believe this type of cytotoxic CD8 T-cell response may be important in clearing HPV infected cells. T-cell responses were also observed at week-52, which was 43 weeks after final treatment with INO-3107 indicating a persistent cellular memory response. Additional analyses are also ...